Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04157309 · ClinicalTrials.gov registry record
Alternating Urine Redox Status Of Consecutive Menstrual Cycles
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 45
- Enrollment target
NCT04157309: Completed study, sponsored by University of Michigan.
NCT04157309 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04157309 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
This study will involve the collection and analysis of urine samples from non-pregnant women to determine the existence of alternating redox status between two consecutive menstrual cycles.
Primary Outcome
The redox potential will be measured over two consecutive cycles to determine the variability in the relative redox status in women's urine.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-01-06 |
| Est. Completion | 2021-01-04 |
What the finished NCT04157309 record still lists
NCT04157309 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04157309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04157309 about?
NCT04157309 is a clinical study titled "Alternating Urine Redox Status Of Consecutive Menstrual Cycles". This study will involve the collection and analysis of urine samples from non-pregnant women to determine the existence of alternating redox status between two consecutive menstrual cycles.
What is the current status of trial NCT04157309?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2020-01-06. Estimated completion is 2021-01-04.
Who is sponsoring clinical trial NCT04157309?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI